CUE | tickerfilter.com

Fundamental analysis

22%

Profitability 25%

Dept financing 6%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-29.61%

1 Month

5,411.06%

3 Months

3,347.27%

6 Months

1,705.07%

1 Year

1,528.96%

2 Year

777.11%

Key data

Stock price

$12.46

P/E Ratio

N/A

DAY RANGE

$10.76 - $17.20

EPS

-$0.28

52 WEEK RANGE

$0.17 - $30.97

52 WEEK CHANGE

$1,549.45

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

97.661 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

1.51

PUBLIC FLOAT

AVERAGE 10 VOLUME

$6,838,439

AVERAGE 30 VOLUME

$24,571,664

Company detail

CEO: Daniel R. Passeri
Region: US
Website: cuebiopharma.com
Employees: 60
IPO year: 2018

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cue Biopharma, Inc. develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.

CUE - Cue Biopharma, Inc.